Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

REVELATION BIOSCIENCES, INC.

REVB · Nasdaq · CIK 0001810560 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

8 Form 4 transaction lines observed in the same window
0 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2023-04-18 · TIDMARSH GEORGE F · $29.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Zygmont Chester Stanley IIIChief Financial Officer
○○○
Rolke JamesChief Executive Officer
○○
Chawla Lakhmir SDirector
○
ROPER JESSDirector
○
CARVER JENNIFERDirector
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-04-18 · TIDMARSH GEORGE F.

Recent Form 4 activity

0Purchases
0Sales
23Other Form 4 lines
22SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,581
Previous report
256
Avg daily volume
36,220
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-04-18TIDMARSH GEORGE FPurchase (P)Common Stock25,000USD 1.16USD 29,000SEC filing ↗
2023-04-17TIDMARSH GEORGE FPurchase (P)Common Stock26,500USD 1.16USD 30,740SEC filing ↗
2022-02-25TIDMARSH GEORGE FPurchase (P)Common Stock20,000USD 1.60USD 32,000SEC filing ↗
2022-02-09TIDMARSH GEORGE FPurchase (P)Common Stock30,000USD 2.55USD 76,500SEC filing ↗
2022-02-08TIDMARSH GEORGE FPurchase (P)Common Stock1,000USD 2.54USD 2,540SEC filing ↗
2022-02-07TIDMARSH GEORGE FPurchase (P)Common Stock42,100USD 2.61USD 109,881SEC filing ↗
2022-02-07TIDMARSH GEORGE FPurchase (P)Common Stock42,100USD 2.61USD 109,881SEC filing ↗
2022-02-04TIDMARSH GEORGE FPurchase (P)Common Stock9,900USD 2.34USD 23,149SEC filing ↗
2022-02-04TIDMARSH GEORGE FPurchase (P)Common Stock7,900USD 2.31USD 18,249SEC filing ↗

Form 4 evidence

23 transaction lines in the latest 365-day window; 56 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-17Zygmont Chester Stanley IIIGift (G)Common Stock208,073USD 0.00USD 0SEC filing ↗
2026-08-17Zygmont Chester Stanley IIIAward / grant (A)Common Stock208,073USD 0.00USD 0SEC filing ↗
2026-08-17Rolke JamesAward / grant (A)Common Stock208,076USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (23 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-17Zygmont Chester Stanley IIIGift (G)Common Stock208,073USD 0.00USD 0SEC filing ↗
2026-08-17Zygmont Chester Stanley IIIAward / grant (A)Common Stock208,073USD 0.00USD 0SEC filing ↗
2026-08-17Rolke JamesAward / grant (A)Common Stock208,076USD 0.00USD 0SEC filing ↗
2026-08-17ROPER JESSAward / grant (A)Common Stock32,011USD 0.00USD 0SEC filing ↗
2026-08-17Chawla Lakhmir SAward / grant (A)Common Stock32,011USD 0.00USD 0SEC filing ↗
2026-08-17CARVER JENNIFERAward / grant (A)Common Stock32,011USD 0.00USD 0SEC filing ↗
2026-04-30Zygmont Chester Stanley IIITax withholding (F)Common Stock13,285USD 1.10USD 14,614SEC filing ↗
2026-04-30Rolke JamesTax withholding (F)Common Stock10,115USD 1.13USD 11,430SEC filing ↗
2026-02-04Zygmont Chester Stanley IIITax withholding (F)Common Stock13,100USD 1.65USD 21,615SEC filing ↗
2026-02-03Rolke JamesTax withholding (F)Common Stock8,521USD 1.86USD 15,849SEC filing ↗
2026-02-03ROPER JESSTax withholding (F)Common Stock1,591USD 1.85USD 2,943SEC filing ↗
2026-02-03Chawla Lakhmir STax withholding (F)Common Stock2,261USD 1.85USD 4,183SEC filing ↗
2026-02-03CARVER JENNIFERTax withholding (F)Common Stock1,661USD 1.87USD 3,106SEC filing ↗
2026-01-08Zygmont Chester Stanley IIIAward / grant (A)Common Stock78,145USD 0.90USD 70,330SEC filing ↗
2026-01-08Rolke JamesAward / grant (A)Common Stock532,829USD 0.90USD 479,546SEC filing ↗
2026-01-08ROPER JESSAward / grant (A)Common Stock41,981USD 0.90USD 37,783SEC filing ↗
2026-01-08Chawla Lakhmir SAward / grant (A)Common Stock41,981USD 0.90USD 37,783SEC filing ↗
2026-01-08CARVER JENNIFERAward / grant (A)Common Stock41,981USD 0.90USD 37,783SEC filing ↗
2025-10-29Zygmont Chester Stanley IIIAward / grant (A)Common Stock390,614USD 1.28USD 499,986SEC filing ↗
2025-10-29Rolke JamesAward / grant (A)Common Stock390,614USD 1.28USD 499,986SEC filing ↗
2025-10-29ROPER JESSAward / grant (A)Common Stock15,625USD 1.28USD 20,000SEC filing ↗
2025-10-29Chawla Lakhmir SAward / grant (A)Common Stock15,625USD 1.28USD 20,000SEC filing ↗
2025-10-29CARVER JENNIFERAward / grant (A)Common Stock15,625USD 1.28USD 20,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerREVB
CIK0001810560
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history56 transaction lines from 2020-10-09 to 2026-08-17
10 P purchase lines · 13 S sale lines · 33 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.